Chudzicka-Czupała, Agata
Hapon, Nadiya
Chiang, Soon-Kiat
Żywiołek-Szeja, Marta
Karamushka, Liudmyla
Lee, Charlotte T.
Grabowski, Damian
Paliga, Mateusz
Rosenblat, Joshua D.
Ho, Roger
McIntyre, Roger S.
Chen, Yi-Lung
Funding for this research was provided by:
National University of Singapore, Department of Psychological Medicine (R-177-000-100-001/R-177-000-003-001/ R177000702733)
National University of Singapore, iHeathtech (R-722-000-004-731)
Article History
Received: 19 October 2022
Accepted: 24 January 2023
First Online: 3 March 2023
Competing interests
: Dr. Roger McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is the CEO of Braxia Scientific Corp. The other authors declare no conflict of interest.